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Abstract Src homology 2 (SH2) domain-containing protein
tyrosine phosphatase substrate 1 (SHPS-1) is a member of the
signal regulatory protein (SIRP) family. The amino-terminal
immunoglobulin-like domain of SHPS-1 is necessary for inter-
action with CD47, a ligand for SHPS-1, which plays an important
role in cell^cell interaction. The intracellular region of SHPS-1,
on the other hand, may act as a scaffold protein, binding to
various adapter proteins. Interestingly, increasing evidence has
shown that SHPS-1 is involved in various biological phenomena,
including suppression of anchorage-independent cell growth,
negative regulation of immune cells, self-recognition of red blood
cells, mediation of macrophage multinucleation, skeletal muscle
differentiation, entrainment of circadian clock, neuronal sur-
vival and synaptogenesis. Recent progress has been made in
attributing these novel exciting functions. Here we discuss how
this interesting molecule works and consider its true role in
biology. + 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Rapid and dynamic regulation of cell surface adhesion re-
ceptors is important for cell migration, growth, extravasation
and invasion. One group of proteins involved in cell adhesion
is the integrins, a family of heterodimeric adhesion receptors
fundamentally important to mediating cell^cell and cell^extra-
cellular matrix (ECM) interactions, communication and rec-
ognition [1]. Clustering of integrins triggers a cascade of intra-
cellular signaling pathways leading to the phosphorylation of
cytoplasmic and cytoskeletal substrates such as focal adhesion
kinase (FAK) and paxillin. Furthermore, modifying integrin
signaling pathways may contribute to cell migration, tumor
invasion and metastasis [2,3]. However, the mechanism by
which cells modulate integrin adhesiveness is not fully under-
stood. It has been shown that several kinds of proteins, in-
cluding immunoglobulin (Ig) superfamily proteins that bind to
integrins, may generally function in concert to mediate both
cell^cell and cell^ECM interactions, which in turn stimulate
cytoskeletal reorganization, migration and invasion. For ex-
ample, the interaction between the Ig superfamily and integ-
rins such as PECAM-1/KvL3 integrins, VCAM-1/K4 integrins,
MadCAM-1/K4 integrins, ICAM/L2 integrins and junctional
adhesion molecule 1/L2 integrin lymphocyte function-associ-
ated antigen 1, mediate leukocyte endothelial/epithelial/¢bro-
blast adhesion governing in£ammatory responses and tumor
metastases [4^7]. Signal regulatory proteins (SIRPs) belong to
the Ig superfamily and relate to integrin signaling cascades.
One of the SIRPs [8,9], Src homology 2 domain-containing
protein tyrosine phosphatase substrate 1 (SHPS-1), is also
known as SIRP K1 [10], BIT (brain Ig-like molecule with ty-
rosine-based activation motifs) [11], P84 [12], MFR (macro-
phage fusion receptor) [13] and MyD-1 [14]. SIRPs appear
ubiquitously expressed as Ig-like transmembrane glycopro-
teins composed of two subgroups, SIRP K and SIRP L (Fig.
1), that overall constitute a subfamily within the Ig superfam-
ily. There are several arguments against using the term ‘fam-
ily’ for SIRP genes; however, we use the word ‘family’ for the
sake of convenience in this review. Among SIRPs, SHPS-1
was ¢rst identi¢ed as a novel tyrosine phosphorylated protein
that binds to Src homology 2 (SH2)-containing protein tyro-
sine phosphatases, SHP-1 and SHP-2, in v-Src-transformed
¢broblasts (SR-3Y1 cells) [8]. Various mitogens such as epi-
dermal growth factor (EGF) and platelet-derived growth fac-
tor (PDGF) induce the tyrosine phosphorylation of SHPS-1
to recruit the tyrosine phosphatases and several SH2-contain-
ing adapters to the plasma membrane [10]. In addition, SHPS-
1 exerts its e¡ects by means of its ligand, CD47, which is also
a transmembrane glycoprotein, to regulate cell^cell interaction
through bi-directional signaling. Up to the present, it has been
shown that SHPS-1 is involved in various biological functions.
2. Expression and structures of SHPS-1 and SIRP family
A protein of the SIRP family consists of three domains: the
extracellular domain, the transmembrane domain and the in-
tracellular domain (Fig. 1). The extracellular domain is fur-
ther divided into three Ig-like regions, an amino-terminal Ig
variable (V) region and two Ig constant (C) regions. The
second and third IgC can be removed by alternative splicing.
At least 15 human members [10], varying in the form of subtle
amino acid di¡erences in the IgV region, have been identi¢ed
in the SIRP family. Two subfamilies termed SIRP K and
SIRP L are distinguished by the length of the cytoplasmic
region. The SIRP is generally considered a colleague of the
Ig-like receptor superfamily proteins, such as killer cell Ig-like
inhibitory receptors (KIRs), Ig-like transcripts (ILTs), leuko-
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cyte Ig-like receptors (LIRs), monocyte/macrophage Ig-like
receptors and paired Ig-like receptors (PIRs) [15], that mod-
ulates signals transduced by the distinct receptors involved in
the function of the cells.
The cytoplasmic region of the SIRP K subfamily proteins
contains two immunoreceptor tyrosine-based inhibitory mo-
tifs (ITIMs) and a proline-rich region near the carboxy-termi-
nus, which represent a binding site for Src homology 3 (SH3)
domain-containing molecules [10,13]. The ITIM is character-
ized by a consensus amino acid sequence of ‘I/VxYxxL’. Phos-
phorylation of the ITIM-associated tyrosine residues enables
recruitment of SHP-1, SHP-2 and SH2 domain-containing
inositol phosphatase, which in turn dephosphorylates speci¢c
protein substrates involved in mediating various physiological
e¡ects. It has been shown that ITIMs are present in a large
group of molecules which negatively regulate cell functions
mediated by certain receptors including KIR, PIR-B, ILT/
LIR-1, leukocyte-associated Ig-like receptor-1, gp49, C-type
lectin inhibitory receptors, FcQ RIIB and CD22.
The SIRP L subfamily, which consists of SIRP L and SIRP-
b2 [16], has a short cytoplasmic region with a positively
charged lysine residue at the juxta-transmembrane domain,
which associates with DAP12 via an ionic transmembrane
domain interaction [17,18]. DAP12, also known as KARAP
[19], has one immunoreceptor tyrosine-based activating motif
(ITAM). Phosphorylation of two tyrosine residues within the
ITAM leads to association with Syk, an SH2 containing cy-
tosolic tyrosine kinase important for receptor signaling. The
SIRP L^DAP12 complex formation leads to tyrosine phos-
phorylation of DAP12, then induces activation of the mito-
gen-activated protein kinase (MAPK) pathway as shown in
myeloid cells [18].
SHPS-1 has a relative molecular weight of 90^120 kDa and
is di¡erentially glycosylated in a species- and tissue-speci¢c
manner [10]. SHPS-1 contains potential N-glycosylation sites
and a large number of serines and threonines that can serve as
O-glycosylation sites [8,9,13,20]. Because the rat SHPS-1 car-
ries no O-linked glycans, the species-speci¢c di¡erence of mo-
lecular weight may be due to the number of potential N-gly-
cosylation sites (NXS/T) that are found: 15 times in rats [8],
17 times in mice [9,12] and ¢ve times in humans [9]. The
tissue-speci¢c di¡erence of glycosylation may be due to the
galactosylation capacity. It has been shown that the di¡er-
ential galactosylation of SHPS-1 determines its cellular bind-
ing speci¢city [21].
The localization of the SHPS-1 gene is identi¢ed on the
human chromosome 20p13 and the mouse chromosome 2
[9,22,23]. Genes of the SIRP family members are also local-
ized on the same chromosome. The open reading frame region
of SHPS-1 is composed of eight exons, corresponding to a
signal peptide, one V-type domain, two C-type domains, a
transmembrane segment and three parts of one cytoplasmic
domain. There are splicing variants of SHPS-1, the cytoplas-
mic VQSL insertion sequence from exon 7, a signal peptide
and a V-type domain in the extracellular part (absence of
exon 3 and 4) and no Ig-like domain in the extracellular
part (absence of exons 2, 3 and 4) [24]. The SHPS-1 mRNA
is ubiquitously expressed in all tissues examined (heart, brain,
spleen, lung, liver, muscles, kidney and testis), being most
abundant in the brain and the spleen [10]. Using immunohis-
tochemistry with a speci¢c anti-SHPS-1 antibody, it has been
shown that SHPS-1 is strongly expressed in myeloid cells
(macrophages, monocytes, granulocytes, dendritic cells) and
neurons [20].
3. Biochemical approach to SHPS-1 function
3.1. A ligand of SHPS-1
CD47, also known as IAP (integrin-associated protein), Rh-
related protein [25] and OA3 (ovarian cancer antigen) [26], is
a highly glycosylated V50 kDa transmembrane glycoprotein
with a broad tissue distribution [27] and is reported to bind to
SHPS-1 as a ligand [28^31]. CD47 was ¢rst identi¢ed as a
copuri¢ed protein with the integrin KvL3 protein from the
placenta and platelets [32]. CD47 also belongs to the Ig re-
ceptor superfamily. The protein consists of an IgV-like do-
main at the amino-terminus and a highly hydrophobic stretch
with ¢ve membrane-spanning segments (also called a multiple
membrane-spanning domain). The carboxy-terminal cytoplas-
mic region can be spliced to several forms ranging in length
from 3 to 36 amino acids [33]. In addition to the SHPS-1,
CD47 has been found to associate physically with several
families of integrins (L1, L2 and L3) and may regulate the
functions of these integrins [33,34]. The Ig domain of CD47
and the amino-terminal Ig domain of SHPS-1 can bind di-
rectly to each other and the binding is su⁄cient to mediate the
following transcellular bi-directional signaling via the respec-
tive cytoplasmic regions [35^40]. Most of the sequence varia-
tion among SIRP K members lies in their IgV domain and this
di¡erence may account for the varied binding a⁄nity of SIRP
K proteins to CD47 [41]. However, there may be additional
Fig. 1. Structure of the SIRP family. The SIRP family consists of
two subfamilies, SIRP K and SIRP L, which di¡er in their cytoplas-
mic domains. The SIRP K contains two ITIMs, which bind to a
SH2 domain-containing protein tyrosine phosphatase and a proline-
rich region in the cytoplasmic domain. The SIRP L has a short cy-
toplasmic domain and a transmembrane domain with a positively
charged lysine residue which associates with DAP12.
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ligands for a single receptor or group of receptors of SIRP K
[41]. SIRP L does not bind to CD47 [41].
3.2. Intracellular signaling of SHPS-1
The cytoplasmic region of SHPS-1 contains two ITIMs
with four tyrosine residues of which phosphorylation can be
induced by various mitogen stimuli such as serum, insulin [8],
lysophosphatidic acid [8], growth hormones (GH) [42], EGF
[10], PDGF [10] and neurotrophic factors [43] as well as in-
tegrin-mediated cell adhesions to laminin or ¢bronectin (FN)
[8,10]. After 1^2 min, mitogenic stimulation leads to tyrosine
phosphorylation of SHPS-1 via the receptor tyrosine kinases;
however, stimulation of integrins by the adhesion of cells to
laminin or FN leads within 15 min to tyrosine phosphoryla-
tion that may be catalyzed by non-receptor tyrosine kinases
such as c-Src [44]. Reduced tyrosine phosphorylation of
SHPS-1 is found in cell lines overexpressing CSK that inhibit
Src family kinases. Furthermore, CSK associates with SHPS-1
endogenously in macrophage, although the physiological role
is not clear [45]. The other Src family kinase, Fgr, has been
reported to potentiate the binding between SHPS-1 and SHP-
1, but does not phosphorylate SHPS-1 directly. In this case,
Fgr seems act as an adapter molecule rather than a kinase to
transduce signals [46]. A cytosolic tyrosine kinase involved in
the STAT pathway, Janus kinase 2 (JAK2), associates with
SHPS-1 when both molecules are overexpressed in cells [42].
The JAK2 phosphorylates SHPS-1 in vitro [47]. The GH-in-
duced tyrosine phosphorylation of SHPS-1 thus seems to be
mediated by JAK2. A cytosolic tyrosine kinase related to
FAK, PYK2, has also been shown to form complexes with
SHPS-1 [48]. Two tyrosines of SHPS-1, Tyr449 and Tyr473,
are phosphorylated after insulin stimulation on RAT1-IR
cells, suggesting that an insulin receptor kinase may phos-
phorylate them [49]. Site directed mutation of either of the
tyrosines abolishes almost all binding to SHP-2 via the SH2
domain. So tyrosine phosphorylation is necessary for the re-
cruitment of SHP-2. In particular, the phosphorylated Tyr449
has a speci¢c a⁄nity to the amino-terminal SH2 domain of
SHP-2, while Tyr473 prefers the carboxy-terminal SH2 do-
main [49]. By a crystal structure analysis, it has been revealed
that the amino-terminal SH2 domain of SHP-2 regulates the
catalytic activity while the carboxy-terminal domain plays an
accessory role [50]. All four phosphotyrosines of SHPS-1 may
serve as substrates for the SHP-2, stimulating the catalytic
activity of the phosphatases [8,49,51]. Recently, the two
adapter proteins FyB/SLAP-130 and SKAP55hom have
been found to associate with SHPS-1 [48]. Furthermore,
SHPS-1 has also been shown to be able to associate with
Grb2 in vitro [10]. The intracellular domain of SHPS-1 may
be important in recruiting these signaling molecules at the site
of transmembrane receptors.
4. Involvement of SHPS-1 in various cell functions
Because SHPS-1 has been shown to bind to various adapter
proteins such as FyB/SLAP 130, SKAP55hom and Grb2
Table 1
Biological function E¡ect Cell or tissue type Stimulation Signalling Reference
(1) Immunology
Mast cell activation downregulation mast cell SHP-1, SHP-2 [35]
NO production upregulation rat alveolar macrophage anti-SIRP [20]
Phagocytosis inhibition mouse splenic red pulp
macrophage
CD47þ/þRBC CD47 [36]
Phagocytosis inhibition mouse splenic red pulp
macrophage
CD47þ/þRBC CD47, SHP-1 [53]
T cell proliferation downregulation memory T cell anti-SHPS-1 Ab CD47 [14]
T cell activation downregulation T cell anti-SHPS-1 Ab CD47 [41]
Cytokine production downregulation dendritic cell T cell CD47 [40]
(2) Hematology
Macrophage fusion murine macrophage CD47 [13,37,38]
Cell aggregation inducible Ba/F3 CD47 [39]
(3) Neurology
Synaptogenesis rat brain ? CD47 [28]
Neural survival rat cerebral cortical neuron
primary culture
BDNF P13K-Akt [56]
Circadian clock phosphorylation of
SHPS-1
hypothalamic suprachiasmatic
nucleus
light SHP-2 [57]
(4) Oncology
Colony formation
(soft agar)
suppression SR3Y1 ? [58]
MAPK activation upregulation CHO-IR, Rat1-IR, NIH3T3 insulin SHP-2 [49]
MAPK activation downregulation v-Fms-transformed NIH3T3 SHP-2 [10]
Motility downregulation glioma cell (U87MG) EGF P13K-Akt [61]
Focus formation downregulation glioma cell (U87MG) EGF P13K-Akt [61]
Apoptosis enhancement glioma cell (U87MG) irradiation P13K-Akt [61]
Focus formation upregulation SHPS-1 mutant ¢broblast cytoplasmic deletion Rho [62]
Migration downregulation SHPS-1 mutant ¢broblast cytoplasmic deletion Rho [62]
MAPK activation no change SHPS-1 mutant ¢broblast EGF SHP-2 [62]
MAPK activation upregulation SHPS-1 mutant ¢broblast IGF-1 SHP-2 [62]
JNK activation upregulation SHPS-1 mutant ¢broblast IGF-1, EGF SHP-2 [62]
(5) Others
Myogenesis inducible myoblast (C2C12) ? SHP-2 [42]
Sca¡old protein macrophage FN SKAP55hom,
FYB/SLAP
[48]
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[10,48], SHPS-1 may work as a sca¡old protein to recruit
these signaling molecules to the close site of the plasma mem-
brane. Recently, SHPS-1 has been identi¢ed as a tyrosine
phosphorylated protein associating with the SHP-2 in myo-
blasts, suggesting that SHPS-1 functions in skeletal muscle
di¡erentiation [52]. Likewise, it has been shown that SHPS-
1 is involved in various cell functions (Table 1). According to
the claim of the referenced paper, the roles of SHPS-1 could
be annotated brie£y as follows.
4.1. In immunology
SHPS-1 works as an inhibitory Ig receptor superfamily and
at times works in cooperation with them. The inhibitory re-
ceptors, which can a¡ect activation signals via ITAM-contain-
ing molecules including BCR IgK and IgL, CD3O, CD3Q,
TCRj, FcORIQ, and DAP12, have a suppressive e¡ect on
the cell function of several hematopoietic lineage cells. A trun-
cated form of SHPS-1 can inhibit IgE-induced cytokine syn-
thesis in mast cells. This inhibition requires SHPS-1 coaggre-
gation with ITAM-bearing high a⁄nity IgE receptors (FcORI)
[35]. An anti-SHPS-1 antibody induces the activation of NO
synthesis in macrophages, suggesting that SHPS-1 generally
inhibits the synthesis [20]. One of the Src kinases, Fgr, asso-
ciates with SHPS-1 and augments the binding between SHPS-
1 and SHP-1 in macrophages, which is responsible at least in
part for decreasing activity of the phagocytosis [46].
It has been shown that CD47 functions as a marker of self-
recognition of red blood cells [36]. CD47-de¢cient cells are
rapidly cleared from the bloodstream by splenic red pulp
macrophages. On the other hand, CD47 on normal red blood
cells prevents this elimination by binding to SHPS-1. The
binding complex between CD47 and SHPS-1 causes tyrosine
phosphorylation of SHPS-1, which is su⁄cient to inhibit mac-
rophage functions such as phagocytosis [36]. It is also re-
ported that inhibition of red blood cell phagocytosis mediated
by FcQ and complement receptors is caused by CD47^SHPS-1
interaction [53]. In this way, the inhibitory signal via the
CD47^SHPS-1 complex appears important in preventing ex-
cess red blood cell clearance or autoimmune hemolytic ane-
mia.
The proliferation of resting memory T cells is signi¢cantly
reduced when the extracellular domain of SHPS-1 is stimu-
lated by an anti-SHPS-1 antibody [14]. However, the binding
of the extracellular domain of SHPS-1 to the CD47 on a
lymphocyte is not su⁄cient for the signaling [41]. The intra-
cellular signaling of SHPS-1 mediated by cell^cell interaction
might be required in certain conditions. CD47^SHPS-1 bind-
ing prevents the phenotypic and functional maturation of im-
mature dendritic cells (DCs) and suppresses interleukin-12
(IL-12) production by mature DCs. The binding also inhibits
IL-12 responsiveness of T cells, which is caused by decreased
IL-12 receptor expression on T cells [40].
Thus, the role of SHPS-1 in the immune system lies mainly
in the negative regulation of phagocytosis, mast cell activation
and dendritic cell activation through CD47 and/or SHP-1
functions. In particular, CD47^SHPS-1 interaction plays nov-
el regulatory roles on immune cells, which may be involved in
the maintenance of immune homeostasis, preventing the esca-
lation of the immune response.
4.2. In hematology
SHPS-1 is also abundantly expressed in myeloid cells in-
cluding monocytes and granulocytes. SHPS-1 expression is
increased at the onset of macrophage fusion, which in turn
results in giant cells or osteoclasts. Interestingly, an anti-
SHPS-1 antibody can inhibit macrophage fusion [13]. The
CD47 may also be involved in this process, because inhibition
of SHPS-1^CD47 complex formation using an anti-CD47
antibody inhibits macrophage multinucleation [37,38]. In an
IL-3-dependent pro-B cell that lacks endogenous SHPS-1, a
Ba/F3 cell, forced expression of SHPS-1 results in a rapid
formation of macroscopic Ba/F3 cell aggregates. The aggre-
gation is mediated by the interaction between the CD47 and
the amino-terminal IgV domain of SHPS-1. Either CD47-null
cells or cells expressing mutant SHPS-1 lacking the IgV can-
not form the aggregation [39]. SHPS-1 is expressed on imma-
ture CD34þCD383CD133þ hematopoietic progenitor cells
and may play an important role in the regulation of early
hematopoiesis [41]. Overall, the function of SHPS-1 on mye-
loid cells seems to overlap with that on immune cells.
4.3. In neurology
In neuronal cells, SHPS-1 is documented as an adhesion
molecule and implicated in neuronal outgrowth and axon
guidance [54]. The SHPS-1 and CD47 form a heterophilic
binding pair that may be involved in bi-directional signaling
at the synapse [28]. The binding functions to modify synaptic
activity or possibly trophic interactions between central neu-
rons [55]. Cerebral cortical neurons can extend their neurites
on SHPS-1-coated substrate. Anti-SHPS-1 antibodies speci¢-
cally inhibit this e¡ect [11]. The heterophilic adhesive proper-
ties and the localization at the synapse suggest that SHPS-1
may also be involved in the regulation of synapse formation
or maintenance [12]. Brain-derived neurotrophic factor
(BDNF)-promoted survival of cultured cerebral cortical neu-
rons was enhanced by the wild-type SHPS-1 and a speci¢c
PI3K inhibitor blocked this enhancement, indicating that its
e¡ect depends on the PI3K^Akt pathway. However, the tyro-
sine phosphorylation of SHPS-1 is not involved in this surviv-
al [56]. SHPS-1 at the rat suprachiasmatic nucleus is highly
tyrosine phosphorylated in the light period compared to the
dark period according to the light cycles [57]. The tyrosine
phosphorylation of SHPS-1 may be involved in light-induced
entrainment of the circadian clock.
4.4. In oncology
It has been reported that v-Src suppresses SHPS-1 expres-
sion and that overexpression of SHPS-1 onto v-Src-trans-
formed ¢broblasts abrogates anchorage-independent cell
growth [58]. Activation of the Ras-MAP-kinase signaling cas-
cade may be critical for the suppression of SHPS-1 expression.
Accordingly, the expression level of SHPS-1 in cancerous tis-
sues of breast carcinomas frequently seems lower than that of
paired normal tissues [59]. SHPS-1 expression is also absent or
signi¢cantly reduced on the majority of myeloid blasts from
patients with acute myeloid leukemia or chronic myeloid leu-
kemia [29]. Moreover, a low level of SHPS-1 expression is
observed in tissues of hepatocellular carcinomas [60]. SHPS-
1 may function as a suppressor against tumorigenesis. How-
ever, it is confusing as to whether SHPS-1 has an e¡ect on
MAPK activation. It has been reported that overexpression of
wild-type SHPS-1 signi¢cantly increased MAPK activity in
response to insulin [49]. In contrast, overexpression of human
SHPS-1 in v-Fms-transformed NIH3T3 cells was reported to
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inhibit MAPK activation [10]. SHPS-1 overexpression caused
reduced cell migration and cell spreading in U87MG glioblas-
toma cells ; however, no MAPK activation was found in the
cells [61]. Likewise, ¢broblasts expressing an SHPS-1 mutant
lacking most of the cytoplasmic region exhibit several e¡ects
on stress ¢ber formation, cell spreading and migration [62]
that is often related to MAPK activation. In ¢broblasts,
growth factor-induced c-Jun N-terminal kinase activation is
enhanced by the SHPS-1 mutant lacking most of the cytoplas-
mic region, although the activation of Ras extracellular signal-
regulated kinase (ERK) is dependent on the kind of growth
factor. Though EGF-induced ERK activation in the SHPS-1
mutant cells is similar to that in wild-type cells, IGF-1-in-
duced ERK activation in the mutant cells is enhanced [62].
Thus, the e¡ects of SHPS-1 on MAPK activation have been
controversially reported. Further studies are needed to estab-
lish the mechanism by which SHPS-1 regulates MAPK signal-
ing.
5. Discussion
The mechanisms by which SHPS-1 exerts these di¡erent
Fig. 2. Schematic representation of the SHPS-1 signaling pathways. Stimulation of a variety of receptors results in tyrosine phosphorylation of
SHPS-1. Receptor kinases and some non-receptor tyrosine kinases can directly phosphorylate SHPS-1. However, other non-receptor tyrosine ki-
nases such as PyK2, FAK, CSK and Fgr only bind to SHPS-1 but cannot phosphorylate it. Tyrosine phosphatases, SHP-1 and/or SHP-2, bind
to and dephosphorylate SHPS-1. Adapter molecules such as Grb2, Fyb/SLAP-130 and SKAP55hom/R also bind to SHPS-1. The signaling
components involve a family of molecules in some cases. The extracellular region of SHPS-1 accept the CD47 as a ligand, which also transdu-
ces a signal through the cytoplasmic domain, that is to say, ‘bi-directional signaling’. SHPS-1 relates with a variety of signal transduction path-
ways.
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e¡ects on the cell have not yet been made clear. In most cases,
probably, SHPS-1 acts as a sca¡old molecule for the SH2-
containing protein tyrosine phosphatases SHP-1 and/or
SHP-2 to activate them (Fig. 2) and the nature of the
SHPS-1 function depends on the function of the phospha-
tases. The roles of the phosphatases in cell signaling also
have not been conclusive. SHP-2 is a cytoplasmic phosphatase
and its membrane localization is important for its activation.
Stimulation of cells with various growth factors and mitogens
activate tyrosine phosphorylation of SHPS-1 and subsequent
binding of SHPS-1 with SHP-2, thereby recruiting SHP-2 at
the vicinity of the cell membrane. In some instances, SHPS-1
negatively regulates MAPK and Akt pathways, although in
such cases SHP-2 may be a mediator. However, there are
several other proteins (Gab-1/2, IRS-1/2, etc.) which act as
potential adapter molecules for SHP-2, or these proteins
may compete with SHPS-1 for SHP-2 binding. In such cases,
activation of SHP-2 is performed by some other protein and
overexpression of SHPS-1 competitively binds SHP-2, making
it less available for the particular adapter. Careful biochemical
studies for the SHPS-1 complex may bring us novel ¢ndings
that are useful for understanding SHPS-1.
There are 17 trinucleotide (CCA) repeats in the 3P untrans-
lated region of the human SHPS-1 gene. It has been suggested
that expansion of trinucleotide repeats is responsible for sev-
eral hereditary pathological disorders, including myotonic
dystrophy, fragile X syndrome, spinal and bulbar atrophy,
Huntington’s disease, spinocerebellar ataxia, Machado^Jeseph
disease and dentatorubral^pallidoluysian atrophy. So, genetic
alteration of the SHPS-1 gene might cause a disease. In par-
ticular, it seems likely that SHPS-1 is deeply involved in im-
munological and hematological disorders, as mentioned
above. Recently, SHPS-1 mutant mice lacking most of the
cytoplasmic region of this protein were generated. The
SHPS-1 mutant ¢broblasts exhibit increased formation of ac-
tin stress ¢bers and focal adhesion, quick-spreading and im-
paired polarized extension and cell migration, which demon-
strates that SHPS-1 plays crucial roles in integrin-mediated
cytoskeletal reorganization and cell motility. In addition,
growth factor-induced activation of MAPK is reduced in
the mutant cells. Taken together, SHPS-1 has a pivotal role
in various important signaling pathways. Further analyses
using gene targeting should unravel the involvement of
SHPS-1 in disorders.
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